<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02229214</url>
  </required_header>
  <id_info>
    <org_study_id>OB-404</org_study_id>
    <nct_id>NCT02229214</nct_id>
  </id_info>
  <brief_title>Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects</brief_title>
  <official_title>A Phase IV, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effect of VI-0521 on the Glomerular Filtration Rate of Healthy Overweight or Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VIVUS, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VIVUS, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is measure the effect of VI-0521 on kidney function.
      Specifically, glomerular filtration rate (GFR) will be measured at baseline, after 4 weeks of
      study treatment, and after an additional 4 weeks of off-treatment recovery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, single-site study in healthy
      overweight or obese male and female volunteers. Oral VI-0521 (combination of phentermine and
      topiramate [PHEN/TPM] extended-release capsule) will be administered daily as follows:

        -  Days 1-3: PHEN/TPM 3.75 mg /23 mg

        -  Days 4-6: PHEN/TPM 7.5 mg /46 mg

        -  Days 7-9: PHEN/TPM 11.25 mg /69 mg

        -  Days 10-28: PHEN/TPM 15 mg /92 mg

      A single dose of Iohexol (a non-radioactive iodine-containing contrast agent) will be
      administered intravenously on three separate occasions.

      The study will include a total of 50 healthy subjects (40 active and 10 placebo), all of whom
      will have overnight stays on 3 separate occasions.

      Total study duration is approximately 10 weeks (2 weeks screening, 4 weeks study treatment, 4
      weeks post treatment follow up).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in iGFR (Glomerular Filtration Rate as Measured by Iohexol Clearance) From Baseline to End of Treatment</measure>
    <time_frame>Baseline, end of treatment</time_frame>
    <description>Method that uses iohexol clearance and body surface area to measure kidney function.
Iohexol is an FDA-approved non-radioactive iodine-containing substance widely used in radio-imaging procedures and as a marker for the measurement of in GFR.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in iGFR (Glomerular Filtration Rate as Measured by Iohexol Clearance) From Baseline to 28 Days After End of Treatment</measure>
    <time_frame>Baseline, 28 days after end of treatment</time_frame>
    <description>Method that uses iohexol clearance and body surface area to measure kidney function.
Iohexol is an FDA-approved non-radioactive iodine-containing substance widely used in radio-imaging procedures and as a marker for the measurement of in GFR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Creatinine From Baseline to End of Treatment</measure>
    <time_frame>Baseline, end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Creatinine From Baseline to 28 Days After End of Treatment</measure>
    <time_frame>Baseline, 28 days after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cystatin C From Baseline to End of Treatment</measure>
    <time_frame>Baseline, end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cystatin C From Baseline to 28 Days After End of Treatment</measure>
    <time_frame>Baseline, 28 days after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With a Decrease of &gt;/= 15% in Iohexol Clearance From Baseline to End of Treatment</measure>
    <time_frame>Baseline, end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With a Decrease of &gt;/= 15% in Iohexol Clearance From Baseline to 28 Days After End of Treatment</measure>
    <time_frame>Baseline, 28 days after end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>VI-0521 (Qsymia)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Days 1-3: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 4-6: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
Days 7-9: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
Days 10-28: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Days 1-28: Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Qsymia</intervention_name>
    <arm_group_label>VI-0521 (Qsymia)</arm_group_label>
    <other_name>VI-0521</other_name>
    <other_name>Phentermine and Topiramate ER (Extended Release)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Sugar pill</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Male or female 18 − 65 years of age, medically healthy with no clinically significant
             screening abnormalities

          -  BMI of ≥27 to ≤45 kg/m2

          -  No use of any medication (prescription, over the counter (OTC) or herbal preparations)
             with the exception of contraception for the entirety of the study

        Key Exclusion Criteria:

          -  Allergy or hypersensitivity to radio contrast media, iodine or shellfish

          -  Plans to significantly alter their diet through fasting, very low caloric intake,
             elimination of certain foods (gluten, milk, meat, etc.) or similar

          -  Plans to undertake a significant change to physical exercise levels (i.e., initiate
             training for a marathon) during the study period

          -  Consumption of a high protein diet or protein/body building meal supplementation
             and/or replacement. The use of any product containing creatine is strictly prohibited

          -  History of glaucoma or increased intraocular pressure

          -  History of bipolar disorder or psychosis, history of psychiatric hospitalization,
             greater than one lifetime episode of major depression, current depression of moderate
             or greater severity, presence or history of suicidal behavior or ideation with some
             intent to act on it

          -  Cholelithiasis (gallstones) within the past 6 months

          -  History of nephrolithiasis (kidney stones)

          -  Evidence of any clinically significant renal, pulmonary, hepatic, psychiatric or other
             condition by history, physical examination or laboratory studies that, in the opinion
             of the investigator, would contraindicate the administration of study medications,
             affect compliance, interfere with study evaluations or confound the interpretation of
             study results as determined by the investigator

          -  Current use of any tobacco products including cigarettes, cigars, pipes, and chewing
             tobacco, or nicotine replacement products (e.g., patch, gum, lozenge, etc.), or
             chronic use within the previous three months prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris Galloway, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2014</study_first_submitted>
  <study_first_submitted_qc>August 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2014</study_first_posted>
  <results_first_submitted>November 17, 2015</results_first_submitted>
  <results_first_submitted_qc>January 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 9, 2016</results_first_posted>
  <last_update_submitted>October 6, 2017</last_update_submitted>
  <last_update_submitted_qc>October 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal function</keyword>
  <keyword>Glomerular Filtration Rate</keyword>
  <keyword>Kidney function</keyword>
  <keyword>Qsymia</keyword>
  <keyword>Iohexol</keyword>
  <keyword>Serum Creatinine</keyword>
  <keyword>Creatinine clearance</keyword>
  <keyword>Renal Clearance</keyword>
  <keyword>VI-0521</keyword>
  <keyword>Healthy volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
    <mesh_term>Phentermine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>VI-0521 (Qsymia)</title>
          <description>Days 1-3: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 4-6: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
Days 7-9: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
Days 10-28: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)
Qsymia</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Days 1-28: Placebo
Sugar Pill</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VI-0521 (Qsymia)</title>
          <description>Days 1-3: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 4-6: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
Days 7-9: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
Days 10-28: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)
Qsymia</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Days 1-28: Placebo
Placebo (sugar pill)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.4" spread="11.07"/>
                    <measurement group_id="B2" value="37.6" spread="9.80"/>
                    <measurement group_id="B3" value="38.2" spread="10.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>Kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.2" spread="4.72"/>
                    <measurement group_id="B2" value="31.3" spread="2.81"/>
                    <measurement group_id="B3" value="32.8" spread="4.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>iGFR</title>
          <units>mL/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95.1" spread="14.05"/>
                    <measurement group_id="B2" value="87.3" spread="9.06"/>
                    <measurement group_id="B3" value="93.6" spread="13.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in iGFR (Glomerular Filtration Rate as Measured by Iohexol Clearance) From Baseline to End of Treatment</title>
        <description>Method that uses iohexol clearance and body surface area to measure kidney function.
Iohexol is an FDA-approved non-radioactive iodine-containing substance widely used in radio-imaging procedures and as a marker for the measurement of in GFR.</description>
        <time_frame>Baseline, end of treatment</time_frame>
        <population>The number analyzed in this outcome measure are those subjects who have both baseline and end of treatment iGFR measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>VI-0521 (Qsymia)</title>
            <description>Days 1-3: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 4-6: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
Days 7-9: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
Days 10-28: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)
Qsymia</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Days 1-28: Placebo
Sugar Pill</description>
          </group>
        </group_list>
        <measure>
          <title>Change in iGFR (Glomerular Filtration Rate as Measured by Iohexol Clearance) From Baseline to End of Treatment</title>
          <description>Method that uses iohexol clearance and body surface area to measure kidney function.
Iohexol is an FDA-approved non-radioactive iodine-containing substance widely used in radio-imaging procedures and as a marker for the measurement of in GFR.</description>
          <population>The number analyzed in this outcome measure are those subjects who have both baseline and end of treatment iGFR measurements.</population>
          <units>mL/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.92" spread="1.28"/>
                    <measurement group_id="O2" value="1.08" spread="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Creatinine From Baseline to End of Treatment</title>
        <time_frame>Baseline, end of treatment</time_frame>
        <population>The number analyzed in this outcome measure are those subjects who have both baseline and end of treatment serum creatininine measurements</population>
        <group_list>
          <group group_id="O1">
            <title>VI-0521 (Qsymia)</title>
            <description>Days 1-3: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 4-6: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
Days 7-9: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
Days 10-28: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)
Qsymia</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Days 1-28: Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Creatinine From Baseline to End of Treatment</title>
          <population>The number analyzed in this outcome measure are those subjects who have both baseline and end of treatment serum creatininine measurements</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.01"/>
                    <measurement group_id="O2" value="0.03" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Creatinine From Baseline to 28 Days After End of Treatment</title>
        <time_frame>Baseline, 28 days after end of treatment</time_frame>
        <population>The number analyzed in this outcome measure are those subjects who have both baseline and 28 days after end of treatment serum creatinine measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>VI-0521 (Qsymia)</title>
            <description>Days 1-3: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 4-6: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
Days 7-9: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
Days 10-28: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)
Qsymia</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Days 1-28: Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Creatinine From Baseline to 28 Days After End of Treatment</title>
          <population>The number analyzed in this outcome measure are those subjects who have both baseline and 28 days after end of treatment serum creatinine measurements.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.01"/>
                    <measurement group_id="O2" value="0.03" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cystatin C From Baseline to End of Treatment</title>
        <time_frame>Baseline, end of treatment</time_frame>
        <population>The number analyzed in this outcome measure are those subjects who have both baseline and end of treatment cystatin C measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>VI-0521 (Qsymia)</title>
            <description>Days 1-3: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 4-6: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
Days 7-9: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
Days 10-28: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)
Qsymia</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Days 1-28: Placebo
Sugar Pill</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cystatin C From Baseline to End of Treatment</title>
          <population>The number analyzed in this outcome measure are those subjects who have both baseline and end of treatment cystatin C measurements.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.01"/>
                    <measurement group_id="O2" value="0.03" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in iGFR (Glomerular Filtration Rate as Measured by Iohexol Clearance) From Baseline to 28 Days After End of Treatment</title>
        <description>Method that uses iohexol clearance and body surface area to measure kidney function.
Iohexol is an FDA-approved non-radioactive iodine-containing substance widely used in radio-imaging procedures and as a marker for the measurement of in GFR</description>
        <time_frame>Baseline, 28 days after end of treatment</time_frame>
        <population>The number analyzed in this outcome measure are those subjects who have both baseline and 28 days after treatment iGFR measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>VI-0521 (Qsymia)</title>
            <description>Days 1-3: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 4-6: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
Days 7-9: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
Days 10-28: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)
Qsymia</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Days 1-28: Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in iGFR (Glomerular Filtration Rate as Measured by Iohexol Clearance) From Baseline to 28 Days After End of Treatment</title>
          <description>Method that uses iohexol clearance and body surface area to measure kidney function.
Iohexol is an FDA-approved non-radioactive iodine-containing substance widely used in radio-imaging procedures and as a marker for the measurement of in GFR</description>
          <population>The number analyzed in this outcome measure are those subjects who have both baseline and 28 days after treatment iGFR measurements.</population>
          <units>mL/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.75" spread="1.49"/>
                    <measurement group_id="O2" value="2.34" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cystatin C From Baseline to 28 Days After End of Treatment</title>
        <time_frame>Baseline, 28 days after end of treatment</time_frame>
        <population>The number analyzed in this outcome measure are those subjects who have both baseline and 28 days after end of treatment cystatin C measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>VI-0521 (Qsymia)</title>
            <description>Days 1-3: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 4-6: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
Days 7-9: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
Days 10-28: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)
Qsymia</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Days 1-28: Placebo
Sugar Pill</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cystatin C From Baseline to 28 Days After End of Treatment</title>
          <population>The number analyzed in this outcome measure are those subjects who have both baseline and 28 days after end of treatment cystatin C measurements.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.01"/>
                    <measurement group_id="O2" value="0.02" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With a Decrease of &gt;/= 15% in Iohexol Clearance From Baseline to End of Treatment</title>
        <time_frame>Baseline, end of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VI-0521 (Qsymia)</title>
            <description>Days 1-3: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 4-6: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
Days 7-9: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
Days 10-28: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)
Qsymia</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Days 1-28: Placebo
Placebo (sugar pill)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With a Decrease of &gt;/= 15% in Iohexol Clearance From Baseline to End of Treatment</title>
          <units>percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With a Decrease of &gt;/= 15% in Iohexol Clearance From Baseline to 28 Days After End of Treatment</title>
        <time_frame>Baseline, 28 days after end of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VI-0521 (Qsymia)</title>
            <description>Days 1-3: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 4-6: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
Days 7-9: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
Days 10-28: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)
Qsymia</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Days 1-28: Placebo
Placebo (sugar pill)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With a Decrease of &gt;/= 15% in Iohexol Clearance From Baseline to 28 Days After End of Treatment</title>
          <units>percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>VI-0521 (Qsymia)</title>
          <description>Days 1-3: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
Days 4-6: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
Days 7-9: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
Days 10-28: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)
Qsymia</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Days 1-28: Placebo
Sugar Pill</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <description>Subject was inside a boom trimming trees when the middle of the metal arm of the boom broke and resulted in subject falling.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular Hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Paraesthesia Oral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysfunctional Uterine Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sinus Congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Craig Peterson, Sr. Director, Clinical Research</name_or_title>
      <organization>VIVUS Inc.</organization>
      <phone>650-934-5200</phone>
      <email>ClinicalTrials@vivus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

